Inside Precision Medicine November 2, 2022
Chris Anderson

Myriad Genetics announced on Tuesday that it acquired consumer-focused prenatal and pediatric genomic test developer Gateway Genomics for $67.5 million in cash. The deal could pay Gateway an additional an additional $32.5 million of cash payments in 2023 and 2024 if certain revenue, volume synergy and EBITDA targets are achieved.

Via the Gateway acquisition, Myriad adds the SneakPeek Early Gender DNA test to its portfolio of women’s health products. According to the companies, SneakPeek is the top selling at-home gender test for expectant families and can deliver results with 99% accuracy only six weeks into the term of a pregnancy. Other products in Myriad’s women’s health line include the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Cancer Therapy and The Intestinal Microbiome
Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions
GLP-1 Prescribing Shifts From Type 2 Diabetes to Obesity
A New Target To Boost Cancer Immunotherapy: LAG-3
STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies

Share This Article